Table 3.
SABA prescriptions in the SABINA III Philippines cohort in the previous 12 months (N=245)
| All (N=245) | Primary Care (n=90) |
Pulmonary Medicine Specialists (n=155) |
||||||
|---|---|---|---|---|---|---|---|---|
| Investigator-classified mild asthma (n=42) | Investigator-classified moderate-to-severe asthma (n=48) | All (n=90) | Investigator-classified mild asthma (n=48) | Investigator-classified moderate-to-severe asthma (n=107) | All (n=155) | |||
| Patients prescribed SABA monotherapy, n (%) | ||||||||
| Yes | 16 (6.5) | 9 (21.4) | 0 (0.0) | 9 (10.0) | 7 (14.6) | 0 (0.0) | 7 (4.5) | |
| No | 229 (93.5) | 33 (78.6) | 48 (100.0) | 81 (90.0) | 41 (85.4) | 107 (100.0) | 148 (95.5) | |
|
| ||||||||
| Number of canisters or inhalers per patient prescribed in the previous 12 months before study visit | ||||||||
| Number of patients | 12 | 6 | 0 | 6 | 6 | 0 | 6 | |
| Mean (SD) | 1.1 (0.3) | 1.2 (0.4) | 0 (0.0) | 1.2 (0.4) | 1.0 (0.0) | 0 (0.0) | 1.0 (0.0) | |
| High dose | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 0 (0, 0 | 1.0 (1.0, 2.0) | 1.0 (1.0, 1.0) | 0 (0, 0) | 1.0 (1.0, 1.0) | |
|
| ||||||||
| Number of canisters or inhalers (as categories) per patient prescribed in the previous 12 months before study visit, n (%) | ||||||||
| 0–2 | 12 (100.0) | 6 (100.0) | 0 (0.0) | 6 (100.0) | 6 (100.0) | 0 (0.0) | 6 (100.0) | |
| ≥3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Missing data | 4 | 3 | 0 | 3 | 1 | 0 | 1 | |
| Total | 12 | 6 | 0 | 6 | 6 | 0 | 6 | |
|
| ||||||||
| Patients prescribed SABA reliever in addition to maintenance therapy, n (%) | ||||||||
| Yes | 99 (40.4) | 1 (2.4) | 28 (58.3) | 29 (32.2) | 4 (8.3) | 66 (61.7) | 70 (45.2) | |
| No | 146 (59.6) | 41 (97.6) | 20 (41.7) | 61 (67.8) | 44 (91.7) | 41 (38.3) | 85 (54.8) | |
|
| ||||||||
| Number of canisters or inhalers per patient prescribed in the previous 12 months before study visit | ||||||||
| Number of canisters | 57 | 0 | 5 | 5 | 1 | 51 | 52 | |
| Mean (SD) | 2.5 (1.6) | 0 (0.0) | 1.2 (0.4) | 1.2 (0.4) | 4.0 (NA) | 2.6 (1.7) | 2.6 (1.6) | |
| Median (min, max) | 2.0 (1.0, 6.0) | 0 (0.0) | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 4.0 (4.0, 4.0) | 2.0 (1.0, 6.0) | 2.0 (1.0, 6.0) | |
| Missing data | 42 | 1 | 23 | 24 | 3 | 15 | 18 | |
|
| ||||||||
| Number of canisters or inhalers (as categories) per patient prescribed in the previous 12 months before study visit, n (%) | ||||||||
| 0–2 | 36 (63.2) | 0 (0.0) | 5 (100.0) | 5 (100.0) | 0 (0.0) | 31 (60.8) | 31 (59.6) | |
| 3–5 | 15 (26.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 14 (27.5) | 15 (28.8) | |
| 6–9 | 6 (10.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (11.8) | 6 (11.5) | |
| >9 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Missing data | 42 | 1 | 23 | 24 | 3 | 15 | 18 | |
| Total | 57 | 0 | 5 | 5 | 1 | 51 | 52 | |
SABA, short-acting β2-agonist; max, maximum; min, minimum; SD, standard deviation.